A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Trial Profile

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms TERI-PRO
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 27 Jun 2017 Results assessing outcomes for Teri-PRO patients (n=455) enrolled in rest of the world (Europe, Canada, and Latin America), presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results assessing disability outcomes, presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results assessing secondary outcomes in patients treated with Teriflunomide, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top